Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Recs

0

AveXis Inc Stock Is Spiking Again Today -- Here's Why

What happened

Shares of AveXis Inc (NASDAQ: AVXS  ) , a clinical-stage biotech company developing gene therapies, are adding to a tremendous run-up this year with a 16.8% gain as of 11:30 a.m. EDT during Friday's session. Yesterday afternoon, the company included phase 1 trial data that could make this a nervous weekend for Biogen Inc (NASDAQ: BIIB  )  and Ionis Pharmaceuticals Inc (NASDAQ: IONS  ) investors.

So what 

The FDA's last new drug approval of 2016, Spinraza for the treatment of spinal muscular atrophy (SMA), might have some competition sooner than anyone had expected. A commercial launch for the RNA antisense therapy discovered by Ionis and marketed by Biogen is still in its infancy. With a lack of competition and a list price of $750,000 for the first year of treatment (then $375,000 for each year thereafter), it's expected to generate about $2 billion in annual sales at its peak.

Raining money onto happy people.

Image source: Getty Images.

Of course, market entry of a viable competitor could limit Spinraza's pricing power, and Avexis could have an early clinical-stage candidate capable of applying that pressure. Results from a phase 1 trial released along with its fourth-quarter earnings report yesterday showed that 15 of 15 SMA patients treated with its lead candidate, AVXS-101, remained event-free at 13.6 months. The study didn't include a placebo group for comparison, but historical data suggests a 25% event-free survival rate at this age.

Also encouraging was a 100% event-free survival rate among all nine patients with follow-up data extending out to 20 months. Based on historical data, the expected event-free rate at this age is just 8%.

Now what

Investors will want to keep their eyes open for data from a planned pivotal trial for AVXS-101 designed to support a marketing application in the EU. After meeting with European regulators, it seems the company has been encouraged to run a 30-patient, single-arm trial using historical data as a comparator. Given the results we've seen so far, that trial and subsequent application look like a slam-dunk.

Unlike Spinraza from Biogen and Ionis Pharmaceuticals, AVXS-101 involves a viral vector that crosses the blood-brain barrier and delivers a functional copy of the SMN gene to the patient's own cells. Another stark contrast is a more convenient dosing regimen. While Spinraza requires several doses each year at $125,000 each, AVXS-101 has the potential of becoming a one-time dose regimen.

10 stocks we like better than AveXis
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and AveXis wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 6, 2017.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 4008537, ~/Articles/ArticleHandler.aspx, 3/23/2017 12:24:38 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
Change up DOW 20731.9 70.6 0.3%
Change up S&P 500 2356.6 8.2 0.4%
Change up NASD 5837.2 15.6 0.3%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

3/23/2017 12:09 PM
AVXS $75.00 Up +2.34 +3.22%
AveXis CAPS Rating: *
BIIB $278.58 Up +0.71 +0.25%
Biogen CAPS Rating: *****
IONS $38.84 Up +0.70 +1.84%
Ionis Pharmaceutic… CAPS Rating: *****

Article registration testing
VISIBLE INTERNALLY ONLY AND ONLY WORKS WITH UNREGISTERED VISITORS

Revisit this page

Clear article's cache and revisit this page

Or, visit the current page, forcing Test ID to article:interrupt:106919 and

Tookie Value = 87881258302192408816144544304155

Advertisement